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Localization of fibroblast growth factor-2 (basic FGF) and FGF tion throughout the body. It is presumed to play impor-
receptor-1 in adult human kidney. tant roles in embryogenesis, vascular homeostasis, ath-
Background. The expression pattern of fibroblast growth erosclerosis, wound healing, angiogenesis, and cancerfactor-2 (FGF-2; basic FGF), a pleiotrophic growth factor, as
[reviewed in 1–6]. In the kidney, experimental evidencewell as one of its receptors (FGFR1), in the kidney is highly
suggests that FGF-2 may serve as an endogenous ampli-controversial.
Methods. Using an approach that combines multiple anti- fier of cytotoxic damage following immune-mediated in-
bodies for immunohistochemistry and correlative in situ hy- jury to glomerular cells [7], and that it may contribute
bridization, we assessed the intrarenal expression of both
to the development of focal segmental glomerulosclero-FGF-2 and FGFR1 in 13 specimens of adult kidney removed
sis [8, 9]. Furthermore, FGF-2 exhibits mitogenic actionsduring tumor nephrectomy.
Results. The FGF-2 expression pattern in the kidneys as on various renal cells, such as mesangial cells [10–12],
detected by immunohistochemistry was variable and depended glomerular endothelial and epithelial cells [13, 14], tubu-
on the antibody used. The most consistent expression of FGF-2 lar epithelial cells [15], and vascular smooth muscle cellsprotein was demonstrated in glomerular parietal epithelial
[5]. Through its mitogenicity and chemotactic action oncells, tubular cells (mainly of the distal nephron), as well as
endothelial and smooth muscle cells, FGF-2 also acts asarterial endothelial cells. These locations also corresponded to
areas of FGF-2 mRNA expression. Additionally, by immuno- an angiogenic factor [3, 5].
histochemistry, FGF-2 protein was detected in arterial smooth Fibroblast growth factor-2 exists in multiple isoforms
muscle cells and occasional podocytes. The expression of in the kidney [11], which arise from alternative splicing.FGFR1 protein and mRNA was most consistently present in
This alternative splicing determines whether the iso-tubular cells of the distal nephron and in vascular smooth
muscle cells. In situ hybridization, but not immunohistochemis- forms localize to the cytoplasm or nucleus [16]. Following
try, also suggested FGFR1 expression in cells that could not cellular release, FGF-2 may be sequestered in the extra-
be precisely identified within the glomerular tuft as well as cellular matrix by binding to heparan sulfate proteogly-
some interstitial cells.
cans (HSPGs) [5]. HSPGs in the cell membrane also actConclusion. These data suggest potential autocrine and par-
as low-affinity receptors for FGF-2 and are necessaryacrine pathways within the FGF-2 system, particularly within
the vascular walls and in the distal nephron, and thereby pro- for signaling by this peptide [17]. In addition to HSPG
vide information for further mechanistic understanding of the low-affinity receptors, four high-affinity FGF receptors
role of the FGF-2 system in human renal disease. have been identified (FGFR1 to FGFR4), of which
FGFR1, FGFR2, and FGFR3 bind FGF-2 [3, 18]. It is
controversial as to whether FGFR4 can also bind FGF-2
Fibroblast growth factor-2 (FGF-2; also known as basic
[19, 20]. Further complexity is added by the fact thatFGF) is a pleiotrophic growth factor with a wide distribu-
FGFR1, FGFR2, and FGFR3 each exist as different
splice variants (for example, IIIb and IIIc variants),
1 See Editorial by Barasch, p. 1156. which influence binding affinities for FGF-2 [3, 18]. Cur-
rently, the best characterized FGF-2 receptor that exhib-Key words: growth factor receptors, smooth muscle cells, renal tubule,
arteries. its the highest binding affinity (Kd 50 to 150 pm) is
FGFR1, also known as flg [18].Received for publication October 16, 1998
Data about renal sites of FGF-2 and FGFR1 expressionand in revised form March 23, 1999
Accepted for publication April 16, 1999 are necessary to achieve a comprehensive understanding
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this respect previous studies have yielded controversial unknown. This antibody recognized FGF-2 in steam-
heated, formalin-fixed sections and in methyl Carnoy’sdata. FGF-2 expression in adult human kidney has been
described as almost absent [21], largely confined to mid- fixed, paraffin-embedded sections.
FGFR1. Flg/C-15 (Santa Cruz Biotechnology) is ansize blood vessels [22] or to tubular cells [23], present in
vessels and cells of Bowman’s capsule but not tubules affinity-purified rabbit polyclonal antibody raised against
a peptide corresponding to amino acids 808 to 822 map-[24], or widely expressed in endothelial, glomerular, tu-
bular and medullary interstitial cells [25]. In the case of ping within the intracellular carboxy terminal region of
human FGFR1. The antibody recognizes FGFR1 inFGFR1, its expression within the human kidney has also
been reported variably, ranging from absent [23] to ex- methyl Carnoy’s fixed, paraffin-embedded sections. The
antibody is nonreactive with FGFR2 (bek), FGFR3, orpression in tubular cells with minimal or negative immu-
nostaining of vessels and glomeruli [26–28]. FGFR4, as determined by Western blotting against the
purified proteins corresponding to these receptors.In our current study, we reassessed the previously
mentioned issues using a combined approach of immu- Clone VBS1 is a murine monoclonal IgM antibody
raised against the extracellular ligand-binding domain ofnohistochemistry with multiple antibody preparations,
as well as correlative in situ hybridization to describe FGFR1 isolated from bovine coronary venular endothe-
lial cells, as described [30]. The antibody was extensivelythe localization of FGF-2 as well as FGFR1 in nondis-
eased adult human kidney. Our data provide a basis characterized previously and shown to specifically immu-
noprecipitate FGFR1 at 120 kDa [30, 31].for further mechanistic understanding of the role of the
FGF-2 system in human renal disease. Tubular markers. EMA, clone E29 (Dako, Carpen-
teria, CA, USA), is a mouse monoclonal IgG2a that is
specific for epithelial membrane antigen [38]. It reacts
METHODS
with normal epithelium in a variety of tissues and has
Tissue selection been characterized by comparative immunocytochemis-
try with several other polyclonal and monoclonal anti-Macroscopically normal-appearing human kidney tis-
sue (N 5 13) obtained fresh from uninvolved portions EMA antibodies [38].
Rabbit anti–Na,K-ATPase (Upstate Biotechnologyof kidneys surgically resected for localized renal cell car-
cinoma was fixed in 10% neutral-buffered formalin, and Inc., Lake Placid, NY, USA) is a whole rabbit antiserum
created against the b-1 subunit of rat Na,K-ATPase [39].was processed and embedded in paraffin according to
conventional techniques. Portions of these kidneys were It was characterized with Western blotting.
also fixed in methyl Carnoy’s solution and were paraffin
Immunohistochemistryembedded as previously described [29]. Four micrometer
sections of all specimens were stained with the periodic Immunohistochemistry was performed on methyl Car-
noy’s fixed, paraffin-embedded tissues following a stan-acid-Schiff reagent, silver methenamine, and hematoxy-
lin and eosin using conventional techniques for light mi- dard avidin-biotin complex (ABC) method. Briefly, sec-
tions were deparaffinized in xylene and rehydrated incroscopy and evaluation of the overall morphology.
graded ethanols. Endogenous peroxidase was blocked
Antibodies by incubation in 3% hydrogen peroxide. The sections
were then incubated for one hour with the primary anti-FGF-2. Basic fibroblast growth factor/147 (bFGF/147;
Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) body diluted in phosphate-buffered saline (PBS) plus
1% bovine serum albumin (BSA). Following washes inand bFGF/Ab2 (Oncogene Science, Cambridge, MA,
USA) are affinity-purified rabbit polyclonal antibodies PBS, the sections were sequentially incubated with bio-
tinylated goat-anti-rabbit or horse-antimouse antibodyraised against a peptide corresponding to amino acids
40 to 63 mapping within the amino terminal region of (Vector Labs, Burlingame, CA, USA), the ABC-Elite
reagent (Vector Labs), and finally 3,39-diaminobenzidinehuman FGF-2. Both antibodies recognized FGF-2 in
methyl Carnoy’s fixed, paraffin-embedded sections. (DAB; with nickel chloride enhancement) was used as
the chromogen. Sections were counterstained withClone 3H3/Ab3 is a murine monoclonal IgG1 antibody
to human recombinant FGF-2 (Oncogene Science). The methyl green and were dehydrated and cover slipped.
Sections of all 13 kidneys were stained with all of thespecific FGF-2 epitope(s) recognized by the antibody is
unknown. This antibody recognized FGF-2 in steam- antibodies. To confirm the staining patterns, all antibod-
ies were also used for immunohistochemistry on acetone-heated, formalin-fixed sections and in methyl Carnoy’s
fixed, paraffin-embedded sections. fixed frozen tissue sections.
Double immunocytochemistry was performed to de-The fourth antibody, clone DE6, is a murine mono-
clonal IgG1 antibody to human recombinant FGF-2 tect FGF-2 expression in combination with the tubular
markers, EMA and Na,K-ATPase. Briefly, slides were(kindly provided by Synergen, Boulder, CO, USA). The
specific FGF-2 epitope(s) recognized by the antibody is incubated with either AB3 or bFGF/147, peroxidase-
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Fig. 1. Western blots show the specificity of each antiserum/antibody
system employed in this study for fibroblast growth factor-2 (FGF-2;
bFGF) with adjacent control lane showing absence of binding to FGF-1 Fig. 2. Solid-phase preabsorption of anti–fibroblast growth factor-2
(aFGF; top). The bottom three Western blots show the ability of these (FGF-2) antibody. (A) Section of human kidney stained with antibody
antibodies to recognize the appropriate FGF-2 substrates in extract of Ab3, which had been preabsorbed with buffer only (Methods section).
whole human kidney. Positive immunostaining of arterial endothelium is evident. (B) The
same section stained with Ab3, which had been preabsorbed with FGF-2
(Methods section). The immunostaining pattern present in (A) is abol-
ished and now is confined to tubular basement membranes.
conjugated secondary antibody and were reacted with
DAB to give a brown colored product. After washing,
residual peroxidase blocking with hydrogen peroxide and
mg/ml (Ab3), or a 1:1000 dilution (DE6), incubated over-normal serum blocking, the slides were then stained with
night at 48C, and then employed for immunostaining.the second primary antibody (EMA or Na,K-ATPase),
Further controls in the case of the bFGF/147 antibodybiotinylated secondary antibody, ABC-HRP (Vector)
included wells coated with the peptide used for immuni-and were reacted with Vector VIP peroxidase substrate
zation (amino acids 40 to 63 mapping within the aminokit (Vector) to give a purple reaction product.
terminal region of human FGF-2; Santa Cruz) at a con-For all samples, negative controls for the immunohis-
centration of 10 or 50 mg/ml. Absorbed antisera weretochemical procedures included substitution of the pri-
then used for repeat immunohistochemical proceduresmary antibody with irrelevant murine monoclonal anti-
as otherwise detailed earlier in this article.bodies or nonimmune rabbit antibody or PBS.
In further control experiments, solid-phase preabsorp-
Western blottingtion of the anti–FGF-2 antibodies was carried out by coat-
To confirm the specificity of the four antibodies againsting recombinant FGF-2 or FGF-1 (both from Oncogene
FGF-2 employed for immunohistochemistry, WesternResearch Products) onto 96-well polystyrene plates over-
blotting was performed using recombinant human FGF-2night at 48C in 0.2 m carbonate buffer (pH 9.6) at a concen-
and FGF-1 (Santa Cruz Biotechnology) and homogenatestration of 2.5 mg/ml. Control wells contained buffer only.
of adult human kidney. Kidney samples were preparedPlates were then washed with PBS and blocked with 1%
as previously described [8, 12]. Samples were electropho-BSA for one hour at room temperature. Following this,
resed on a 15% sodium dodecyl sulfate-polyacrylamideone of the four anti–FGF-2 antibodies was added at a
concentration of 1 mg/ml bFGF/147, 4 mg/ml (Ab2), 0.5 gel (SDS-PAGE) and were then blotted onto 0.2 mm
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Table 1. Summary of immunohistochemistry and in situ hybridization data on the expression of FGF-2 in mature human kidney
Immunohistochemistry with anti-FGF-2 antibody
Cell-type or intrarenal In situ
structure bFGF/147 Ab2 Ab3 DE6 hybridization
Arterial endothelial cells 1 6 1 1 1
Vascular smooth muscle cells 1 6 6 1 2
Neointimal smooth muscle cells 1 6 6 1 2
Vascular adventitial cells 2 2 2 1 2
Venous endothelium 2 2 6 1 2
Peritubular endothelium 6 2 6 1 2
Cells within glomerular tuft 1 6 6 1 2
Glomerular basement membrane 2 2 2 2 NA
Podocytes 6 2 2 6 2
Parietal glomerular epithelial cells 1 1 1 1 6
Tubules 1a 1a 1a 1a 1a
Interstitial cells 6 6 6 1 6
Tubular basement membrane,
interstitial matrix 6 2 2 6 NA
Interstitial infiltrates 2 2 2 6 2
Symbols are: (1) positive immunostaining or expression of mRNA; (6) positive immunostaining or expression of mRNA under some circumstances or staining
conditions only (see text); (2) absent immunostaining or mRNA expression. NA is not applicable.
a See text for further details
nitrocellulose membranes. The blots were blocked with cipitated, resuspended in nuclease-free water containing
10 mmol dithiothreitol, and stored at 2208C. Probes5% BSA in PBS for one hour and then incubated with
primary antibody or an equal concentration of normal were used within 48 hours.
Pilot studies were performed with the flg and FGFR1brabbit IgG or monoclonal mouse IgG1 (Dako) diluted
in Tris-buffered saline containing 1% BSA for two hours probes in which the 35S-UTP–labeled probes were treated
to limited alkaline hydrolysis in order to generate frag-at room temperature. After washing, the blots were incu-
bated with alkaline phosphatase-conjugated goat anti- ments of approximately 200 bp. The hydrolyzed and full-
length transcripts were used on replicate sections. The inrabbit IgG or goat antimouse antibody (Dako) for one
hour. The blots were then visualized with 5-bromo-4- situ hybridization signal was equivalent with both probes,
and the full-length probes were used in subsequent ex-chloro-3-indolylphosphate-nitro blue tetrazolium (BCIP-
NBT). periments to maintain high hybridization stringency.
In situ hybridizationMolecular probes
The following probes were used: (a) a 1300 bp cDNA Kidney tissues, which were fixed in 10% formalin and
embedded in paraffin, were deparaffinized following stan-corresponding to nucleotides 435 to 1735 of human FGF-2
cloned into pKS1 Bluescript (kindly provided by I. Drum- dard protocol. In situ hybridization was then performed
as described previously [32, 33]. Briefly, the sections weremond, Charlestown, MA, USA); (b) pCD115, a 1200 bp
flg cDNA corresponding to the region encoding the en- washed with 0.5 3 standard saline citrate (SSC) and
digested with proteinase K (1 mg/ml; Sigma Chemicaltire extracellular domain, cloned into the pGEM 1 plas-
mid (kindly provided by Volkard Lindner, Department Co., St. Louis, MO, USA) in Tris buffer. Several 0.5 3
SSC washes were followed by prehybridization for twoof Pathology, University of Washington, Seattle, WA,
USA); and (c) a 4 kb cDNA encoding the full-length hours. The hybridizations were started by adding 500,000
cpm of 35S-labeled riboprobe in 50 ml of prehybridizationsequence of human FGFR1b ligated into the PCR-2
plasmid. All constructs were linearized and transcribed buffer and allowed to proceed overnight at 508C. After
hybridization, sections were washed with 0.5 3 SSC,into an antisense or sense riboprobe, as described pre-
viously [34]. Briefly, the transcription reaction mixture treated with RNase A, washed in 2 3 SSC, followed by
three high-stringency washes in 0.1 3 SSC/Tween 20contained 1 mg cDNA (sense or antisense), [35S]-uridine
triphosphate ([35S]-UTP), adenosine triphosphate (ATP), (Sigma) at 508C, and several 2 3 SSC washes. After the
tissue was dehydrated and air dried, it was dipped incytidine 59-triphosphate (CTP) and guanosine 59-triphos-
phate (GTP), RNAsin, dithiothreitol, Tris, and either NTB2 nuclear emulsion (Eastman Kodak, Rochester,
NY, USA) and exposed in the dark at 48C for two weeks.SP6 or T7 polymerase. After 75 minutes, the template
DNA was digested by adding DNAse and incubating at After developing, the sections were counterstained with
hematoxylin and eosin, dehydrated, mounted, and378C for an additional 15 minutes. Free nucleotides were
separated with a Sephadex G-50 column. The collected viewed. Positive cellular labeling was defined as five or
more silver grains concentrated over a single cell.fraction containing labeled probe was then ethanol pre-
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Fig. 3. Vascular immunostaining for fibroblast growth factor-2 (FGF-2). Serial sections of a small cortical artery stained with the four anti–FGF-2
antibodies. (A) Polyclonal antibody bFGF/147. Positive immunostaining of endothelial cells in a nuclear pattern, as well as weak staining of medial
smooth muscle cells, is present. (B) Polyclonal antibody Ab2. Weak staining of endothelial cells in a nuclear pattern as well as staining of tubular
cells is noted. (C) Monoclonal antibody Ab3. Strong nuclear staining of endothelial cells is present. (D) Monoclonal antibody DE6. Positive
immunostaining of endothelial cells, medial smooth muscle cells, adventitial cells, interstitial cells, and tubular cells is present in a cytoplasmic pattern.
RESULTS extensively in kidney homogenates; Fig. 1) [8]. Each of
the antibodies recognized recombinant FGF-2, with aMorphological findings in adult human kidneys
major band detected at approximately 18 kDa and a
By conventional light microscopy, the adult kidney second weaker band at approximately 36 kDa. None of
specimens were, for the most part, morphologically nor- the antibodies showed cross-reactivity with FGF-1. In
mal, although focal areas demonstrating variable degrees addition, the three commercially available antibodies
of focal and segmental glomerulosclerosis, tubular atro- recognized several bands in the tissue lysates with ap-
phy, interstitial fibrosis, and arteriosclerotic changes proximate molecular weights of 18, 28, 30, and 36 kDa.
were present. These changes were completely consistent The appearance of multiple FGF-2 variants at these ap-
with nephrosclerotic changes of aging and were fre- proximate molecular weights has been previously re-
quently concentrated in the immediate subcapsular cor- ported in both human tissue [34] and cultured cells [12,
tex. None of these changes were extensive or indicative 35], and is consistent with the presence of several FGF-2
of a superimposed primary disease process. isoforms.
In further studies, we investigated the effect of an
Characterization of anti–FGF-2 antibodies incubation of the bFGF/147 or Ab2 antibody with an
All four antibodies were used in Western blotting ex- excess of recombinant human FGF-2 prior to immuno-
periments to detect recombinant FGF-1 and recombi- histochemistry. Similar to previous reports [36, 37], this
nant FGF-2 (Fig. 1). Additionally, the Ab2, Ab3, and did not abolish the positive immunostaining with the
bFGF/147 antibodies were used in Western blotting ex- antibodies but rather resulted in prominent staining of
periments using lysates derived from adult kidney cortex tubular basement membranes and adjacent interstitial
matrix (data not shown).(the DE6 antibody has previously been characterized
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with immobilized complete FGF-2 (Fig. 2). Immuno-
staining with the Ab2 and DE6 antibodies was moder-
ately reduced but not abolished following incubation
with immobilized complete FGF-2 (data not shown).
Immunostaining with the bFGF/147 was reduced in sam-
ples that were incubated with the immobilized immuniz-
ing peptide (partial FGF-2; data not shown). For all
antibodies, a control incubation with immobilized FGF-1
instead of FGF-2 yielded a staining pattern that was
similar to that observed with nonabsorbed antibody to
FGF-2 (data not shown). Furthermore, in most instances,
some enhancement of tubular basement membrane
staining was noted in those samples that had been incu-
bated with immobilized FGF-2 (Fig. 2). This suggests
that, analogous to the experiments in which antibody
was incubated with excess FGF-2 (discussed earlier in this
article), some leakage of the immobilized antigen may
have occurred, which resulted in subsequent binding of
the FGF-2/anti–FGF-2 antibody complex to the sections.
FGF-2 expression in adult human kidneys
Immunohistochemical findings and the findings of in
situ hybridization in the kidneys are summarized in
Table 1. The usage of the four different antibodies
against FGF-2 yielded staining patterns that were rela-
tively similar, but some important differences evolved
with respect to tissue structures exhibiting positivity, as
well as to the intracellular localization of immunoreac-
tive FGF-2 (that is, cytoplasmic stain vs. nuclear stain;
Table 1). No qualitative differences in localization pat-
terns were obtained when frozen, cryostat tissue sections
were used in place of fixed tissue sections for the immu-
nohistochemical procedures.
Vasculature. Arterial endothelial cells consistently
expressed FGF-2 protein with all four antibodies used
(Fig. 3). Except for the DE6 antibody, which yielded a
cytoplasmic signal, all other antibodies localized detect-
able FGF-2 to the nuclei of the endothelial cells (Fig. 3).
Compared with endothelial cells, the staining intensity in
vascular smooth muscle cells of the vascular media was
weaker, but in many instances, positive immunostaining
of variable degrees was observed (Fig. 3). Adventitial
cells only exhibited immunoreactivity with the DE6 anti-Fig. 4. Vascular expression of fibroblast growth factor-2 (FGF-2)
mRNA. Tangential section of an arcuate artery probed with antisense body (Fig. 3D). In atherosclerotic vessels, FGF-2 immu-
probe (bright field: A; dark field: B), as well as with a sense probe (C). noreactivity of variable degrees was noted in vascular
The hybridization signal is confined to the endothelial layer, whereas
smooth muscle cells of the neointima with all four anti-the signal over medial smooth muscle cells is indistinguishable from
background. Arrowheads indicate internal elastic membrane. bodies. By in situ hybridization, FGF-2 mRNA was de-
tectable in endothelial cells but not in medial or neointi-
mal smooth muscle cells nor adventitial cells of renal
arteries (Fig. 4).
Given this observation, we also carried out solid-phase Compared with arterial endothelial cells, the degree
preabsorption experiments with the four anti–FGF-2 an- of detectable immunostaining was lower in endothelial
tibodies. In these experiments, endothelial, tubular, and cells of peritubular capillaries and veins, where it ranged
glomerular cell staining was completely abolished when from absent to focally detectable with the four antibodies
employed (Figs. 5 and 7). In situ hybridization also failedthe Ab3 monoclonal anti–FGF-2 antibody was incubated
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Fig. 5. Glomerular immunostaining for fibroblast growth factor-2
(FGF-2). (A) Antibody bFGF/147. Positive immunostaining of rare
intraglomerular cells and of parietal glomerular epithelial cells in a
nuclear pattern is shown. (B) Antibody bFGF/147. In a different speci-
men, a staining pattern suggestive of cytoplasmic staining in podocytes
is noted. (C) Antibody Ab2. Nuclear staining is confined to endothelial
cells at the hilus (arrowheads) and parietal glomerular epithelial cells.
(D) Antibody Ab3. Positive immunostaining of rare intraglomerular
cells and of parietal glomerular epithelial cells in a nuclear pattern. (E)
Antibody DE6. Positive immunostaining of all glomerular cell types
including parietal glomerular epithelial cells as well as of distal tubular
cells, peritubular capillary endothelial cells, and interstitial cells is
present.
to detect FGF-2 mRNA expression in capillary or venous endothelial cells (Fig. 5E). No staining of the glomerular
basement membrane was noted. Staining of podocytesendothelium.
Glomeruli. Within the glomerular tuft, that is, within was inconsistently present with the polyclonal bFGF/147
and the monoclonal DE6 antibody, but rare to absentmesangial and endothelial cells as well as leukocytes of
adult kidneys, a variable number of cells displayed immu- with the two other antibodies (Fig. 5). In contrast, pari-
etal glomerular epithelial cells stained positively usingnoreactivity with all four antibodies tested (Fig. 5).
Whereas in some cases, the infrequency of the cells sug- all four antibodies, albeit with patterns that ranged from
cytoplasmic to nuclear localization (Fig. 5). By in situgested labeling of circulating or infiltrating leukocytes
(Fig. 5A), it was more widespread with the DE6 antibody hybridization, FGF-2 mRNA was detectable in occa-
sional parietal glomerular epithelial cells only (Fig. 6).and consistent with FGF-2 expression in mesangial and
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Fig. 6. Glomerular in situ hybridization for fibroblast growth factor-2
(FGF-2) mRNA. (A) Light and (B) dark field image. Hybridization signal
is indistinguishable from background within the glomerular tuft but is
present in rare glomerular parietal epithelial cells (arrowheads), as well
as distal tubular cells (arrows).
FGF-2 protein and mRNA expression was markedly re-
duced in sclerotic glomeruli (data not shown).
Tubules. By immunohistochemistry using the four an-
tibodies, tubules consistently expressed FGF-2 in adult
kidneys (Figs. 5 and 7). In situ hybridization also con-
firmed the presence of FGF-2 synthesis in tubular cells
(Fig. 8). A more detailed analysis of the tubular segments
was based on morphological criteria to identify tubular
Fig. 7. Tubular immunostaining for fibroblast growth factor-2 (FGF-2).segments. Proximal tubules were identified in the cortex
(A) Antibody bFGF/147. Medulla. Positive immunostaining of collect-by their prominent brush border membrane, distal tu-
ing duct cells as well as of peritubular capillary endothelial cells in a
bules by their more cuboidal and smaller cells, as well as nuclear pattern is present. (B) Antibody Ab3. Cortex. Positive immuno-
staining of cells of the macula densa in a nuclear pattern. (C) Antibodya less prominent brush border membrane and collecting
DE6. Cortex. Staining is present in cells of distal but not proximalducts by the absence of a brush border membrane and
tubules, a dilated distal tubule as well as in interstitial cells and peritubu-
columnar cells. Based on these criteria, the detailed anal- lar capillary endothelial cells.
ysis revealed that particularly the epithelium of distal
tubules, including the macula densa, as well as collecting
ducts, exhibited positive immunolocalization (Fig. 7).
To confirm the localization of FGF-2 in specific tubularStaining patterns within individual cells again were vari-
segments, double immunohistochemistry was performedable and ranged from cytoplasmic staining (Fig. 7C) to
with Ab3 and bFGF/147 in combination with markersexclusively nuclear staining, especially in the case of
staining with the AB3 monoclonal antibody (Fig. 7 A, B). of distal tubules such as EMA and Na,K-ATPase (Fig. 9).
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Fig. 9. Double immunohistochemistry. (A) bFGF-147 (brown) and
EMA (purple) colocalize in distal tubules. (B) In a replicate tissue
section, Ab3 (brown) and Na,K-ATPase (purple) also colocalize in
distal tubules.Fig. 8. Tubular in situ hybridization for fibroblast growth factor-2
(FGF-2) mRNA. (A) Light and (B) dark field image. Corticomedullary
junction. Hybridization signal is present in distal tubules and collecting
ducts but not in proximal tubular cells or interstitial cells.
These experiments demonstrated colocalization of the
markers with FGF-2 and thus confirm that FGF-2 is
primarily expressed in cells of the distal tubule.
Interstitium. Using the DE6 monoclonal antibody
against FGF-2, positive immunostaining was detectable
in the interstitium of adult kidneys (Figs. 3D, 5E, and
7C.). Reactivity was weak to absent when the other anti-
bodies to FGF-2 were employed, and only rare cells,
which often appeared to represent peritubular capillary
endothelial cells, exhibited signal. Staining of the extra-
cellular matrix and/or the tubular basement membrane
Fig. 10. Interstitial immunostaining for fibroblast growth factor-2was occasionally observed, particularly in areas with in-
(FGF-2) in renal interstitial fibrosis. Antibody bFGF/147. In an area
terstitial fibrosis, using the bFGF/147 and DE6 antibod- of cortical fibrosis, immunoreactivity is present in distal tubular cells
and also in the extracellular matrix, particularly the tubular basementies (Fig. 10). In focal interstitial infiltrates, the majority
membrane of some tubules (arrowheads).of mononuclear cells failed to exhibit positive immuno-
staining with three of the four anti–FGF-2 antibodies,
whereas the DE6 antibody occasionally yielded positive
staining in a high percentage of infiltrating cells (data lems, these cells could not be phenotyped. Their rarity,
not shown). By in situ hybridization, only very rare inter- however, would suggest that they did not represent in-
stitial cells contained FGF-2 mRNA (data not shown). trinsic renal cells, but rather infiltrating or circulating
leukocytes. As in the case of immunohistochemistry, theBecause of the rarity of such cells and technical prob-
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Table 2. Summary of immunohistochemistry and in situ they represented circulating leukocytes. In contrast to
hybridization data on the expression of FGFR1 in
the immunohistochemical findings, in situ hybridizationmature human kidney
with both cDNAs for FGFR1 demonstrated mRNA ex-
Immunohisto- pression in cells of the glomerular tuft (Fig. 12 B, C).chemistry with In situ
The signal was usually not detectable at the edge of theanti-FGFR1 hybridization
antibody with probe glomerular tuft (Fig. 12 B, C), suggesting that the mRNACell-type or intrarenal
structure VBS1 Flg/C-15 FGFR1b flg expression was mostly derived from mesangial and/or
glomerular endothelial cells and/or infiltrating/circulat-Arterial endothelium 2 2 2 2
Vascular smooth muscle cells 6 6 1 1 ing leukocytes. Parietal glomerular epithelial cells occa-
Neointimal smooth muscle cells 6 6 1 1 sionally stained positively with the Flg/C15 antibody
Vascular adventitial cells 2 2 2 2
(Fig. 12D) and expressed FGFR1 mRNA (Fig. 12 B, C),Venous endothelium 2 2 2 2
Peritubular endothelium 2 2 2 2 whereas no signal was obtained over Bowman’s capsule
Cells within glomerular tuft 6 6 1 1 with the VBS1 antibody.
Glomerular basement membrane 2 2 NA NA
Tubules. Immunohistochemistry with the two anti-Podocytes 2 2 2 2
Parietal glomerular epithelial cells 2 6 6 6 FGFR1 antibodies as well as in situ hybridization with
Tubules 1a 1a 1a 1a the two cDNAs consistently demonstrated FGFR1 pro-
Interstitial cells 6 6 6 6
tein and mRNA expression in tubular cells. Most of theTubular basement membrane,
interstitial matrix 2 2 NA NA tubular segments were identified as loops of Henle, distal
Interstitial infiltrates 6 6 6 6 tubules, and collecting ducts (Figs. 11A, 12 A–C, and 13).
Symbols are: (1) positive immunostaining or expression of mRNA; (6) posi- The immunohistochemical staining pattern within the
tive immunostaining or expression of mRNA under some circumstances or stain-
positive tubular segments was not uniform, and staininging conditions only (see text); (2) absent immunostaining or mRNA expression.
NA is not applicable. of individual cells ranged from negative to staining of
a See text for further details
the cell membrane to diffuse cytoplasmic stain (Fig. 13).
In the absence of specific immunohistochemical markers
of the collecting duct cells, it was not possible to unequiv-
majority of mononuclear cells in interstitial infiltrates ocally assign FGF-1 expression to either intercalated or
did not exhibit detectable amounts of FGF-2 mRNA. principal cells.
Interstitium. By immunohistochemistry, rare cells in
FGFR1 expression in adult kidneys the interstitium of normal kidneys stained positively for
Immunohistochemical findings and the findings of in FGFR1 using either antibody (Fig. 12D). No staining of
situ hybridization in the kidneys are summarized in the extracellular matrix or tubular basement membrane
Table 2. was noted. No enhanced staining was noted in areas of
Vasculature. Within the arterial vasculature, endothe- interstitial fibrosis. Most leukocytes in focal infiltrates
lial cells failed to express FGFR1 in adult kidneys with also failed to express FGFR1 protein, but in some cells,
both the polyclonal Flg/C-15 and monoclonal VBS1 anti- strong staining was noted. In situ hybridization in normal
body (Fig. 11 A, B). By in situ hybridization with either kidneys demonstrated strong FGFR1 mRNA expression
of the two FGFR1 probes, most arterial endothelial cells in some cells of the interstitium, but no enhanced mRNA
also did not appear to express mRNA (Fig. 11 C, D), expression in areas of interstitial fibrosis (Fig. 12 B–C).
but the expression of FGFR1 mRNA in adjacent smooth As in the case of immunohistochemistry, however, most
muscle cells at times rendered the definitive localization cells in mononuclear infiltrates failed to exhibit FGFR1
of grains to specific cell types difficult. Smooth muscle mRNA expression, again suggesting that either a sub-
cells stained positively to a variable degree for FGFR1 fraction of leukocytes and/or rare intrinsic interstitial
protein using the two anti-FGFR1 antibodies. Further- cells express FGFR1 mRNA.
more, both FGFR1 mRNA and protein were detectable
in neointimal lesions in atherosclerotic vessels (Fig. 11
DISCUSSIONB–D). Vascular adventitia failed to express FGFR1 pro-
Using an approach that combines multiple antibodiestein or mRNA.
for immunohistochemistry and in situ hybridization, weCapillary and venous endothelium did not express
demonstrate intrarenal expression of both FGF-2 andFGFR1 mRNA or protein in normal kidneys.
FGFR1 under all conditions employed. This study isGlomeruli. By immunohistochemistry, most glomeru-
noteworthy for the heterogeneity of some of the findings.lar cells were unreactive with both of the anti-FGFR1
This contrasts with previous studies on other cytokinesantibodies (Figs. 11A and 12A). Frequently, however, a
and their receptors in human kidney, in which we havefew individual cells within the glomerular tuft stained
used the same approach and obtained consistent proteinpositively for FGFR1 (Figs. 11A and 12A). These latter
cells often localized to capillary lumina, suggesting that and mRNA data [29, 32, 33, 38, 39]. In the case of FGF-2,
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Fig. 11. Renal vascular expression of fibroblast growth factor receptor-1 (FGFR1) protein and mRNA. (A) Adult cortex, polyclonal antibody
Flg/C-15. FGFR1 is expressed in smooth muscle cells of the vascular media as well as in cells of a distal tubule and a single cell within the
glomerular tuft (arrowhead). (B) Artherosclerotic vascular damage with neointima formation, stained with monoclonal antibody VBS1. FGFR1
is expressed in vascular smooth muscle cells of both media and neointima but not in endothelial cells. (C and D) Arcuate artery with moderate
neointima formation; in situ hybridization using the FGFR1b cDNA, bright and dark field image. FGFR1 mRNA localizes to smooth muscle cells
of the media and neointima, but not to endothelial cells.
it has been reported that fixation conditions have a major ment membranes and the extracellular matrix [37]. This
bound exogenous FGF-2 is then labeled in the subse-influence on the apparent localization of the cytokine
within rat kidney [35] and also on the apparent intracellu- quent tissue immunohistochemical procedures. How-
ever, using Western blots, as well as absorption of thelar localization of FGF-2, that is, localization to nuclear
versus cytoplasmic compartments [40, 41]. Although dif- antibodies to a solid phase, we demonstrate that all four
antibodies react specifically with recombinant FGF-2 andferences in fixatives may account for some of the discrep-
ancies between our in situ hybridization data and immu- do not cross-react with FGF-1. We therefore conclude
that the different expression patterns of FGF-2 may re-nostaining results, all material for immunohistology was
fixed and processed in the same manner. Consequently, sult from the complexity of the FGF-2/FGFR1 system,
particularly its multiple isoforms, and the resulting differ-the apparent variability, particularly in the case of FGF-2
expression, must be attributed to differences among the ences in antibody specificities [42]. Furthermore, in the
case of FGF-2, it has been described that mRNA expres-antibodies employed for immunostaining.
To demonstrate that the different staining patterns sion is much less widespread in comparison to protein
expression, which reflects the fact that FGF-2 is mostlywith the FGF-2 antibodies were specific, several control
experiments were performed. Similar to previous reports stored in the cytoplasm and/or extracellular matrix and
synthesized only on demand [43]. Similar considerations[36, 37], we noted that it was not possible to demonstrate
specificity of the immunostaining pattern by preabsorp- also apply to FGFR1, where again, the occurrence of
different splice variants may result in apparently differ-tion of the antibodies with excess antigen. Rather, in this
case, there is binding of some of the exogenous FGF-2 ent staining patterns.
Within glomeruli, the demonstration of FGF-2 proteinused in the absorption procedures to HSPGs within base-
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Fig. 12. Glomerular expression of fibroblast growth factor receptor-1 (FGFR1) protein and mRNA. (A) Adult cortex, monoclonal antibody VBS1.
FGFR1 is expressed in a single cell within a lumen of the glomerular tuft as well as in some cells of distal tubules. (B) Renal cortex, polyclonal
antibody Flg/C-15. FGFR1 is expressed in parietal glomerular epithelial cells, rare cells within the glomerular tuft, some distal tubular cells, as
well as in rare interstitial cells. (C) Light and (D) dark field image. Renal cortex with moderate interstitial fibrosis; in situ hybridization with the
FGFR1b cDNA. FGFR1 mRNA is present within cells of the glomerular tuft, rare parietal glomerular epithelial cells (arrowheads), and cells of
distal tubules.
in a typical mesangial pattern was exceptional in this low translational efficacy in the case of FGFR1. This
assumption is consistent with the literature, in which Fordstudy. This contrasts with findings in rats, where, using
comparable conditions (methyl Carnoy’s fixed, paraffin- et al describe prominent expression of FGFR1 mRNA
(with low to absent expression of FGFR2, FGFR3, andembedded tissue, DE6 monoclonal antibody), we noted
prominent expression of FGF-2 in mesangial cells in vivo FGFR4 mRNA) in normal rat glomeruli [44], whereas
we and others have reported absent or only minimal[11]. Rather, in the present study, occasional visceral
and in particular parietal glomerular epithelial cells were FGFR1 protein expression in both normal rat and human
glomeruli [8, 23, 28].most consistently positive for FGF-2. Similarly, Stein-
Oakley et al, using a different anti–FGF-2 monoclonal Tubular cells, mainly of the distal nephron (distal tu-
bules, collecting ducts), were one of the two sites in whichantibody on cryostat, paraformaldehyde-fixed sections,
described FGF-2 expression in nuclei of parietal glomer- we consistently detected FGF-2 mRNA and protein un-
der all experimental conditions. Previously, Hughes andular epithelial cells in normal human kidney [25]. In
contrast to FGF-2, the expression of FGFR1 in glomeruli Hall, using a polyclonal anti–FGF-2 antibody (Oncogene
Science, NY, USA) in formalin-fixed tissues, as well asin this study was notable for the relative abundance of
mRNA transcripts but low intraglomerular expression Stein-Oakley et al also described tubular FGF-2 protein
expression without commenting on the specific localiza-of FGFR1 protein. Because our anti-FGFR1 antibodies
were directed against different portions of the FGFR1, tion [23, 25]. However, in the rat, a detailed study by
Cauchi et al using various fixation conditions and twothe predominance of a particular splice variant is unlikely
to underlie this observation. Rather, our data suggest polyclonal anti–FGF-2 antibodies is consistent with our
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In the renal interstitium of adult human kidneys, only
rare cells expressed FGF-2 or FGFR1 under most condi-
tions of our study. In contrast to Stein-Oakley et al, we
failed to observe increased cell-associated FGF-2 expres-
sion in fibrotic areas [25]. Rather, FGF-2 protein in these
instances localized to the extracellular matrix and tubu-
lar basement membrane, that is, the known extracellular
binding sites for FGF-2 [37]. Another interesting obser-
vation of our current study was that FGFR1 appeared
to label some circulating leukocytes in both the renal
interstitium and glomerular capillaries, supporting ob-
servations of Kerby et al, who noted FGFR1 protein
expression in some interstitial inflammatory cells of re-
jecting transplants [27].
Apart from tubular cells, the second intrarenal site at
which we most consistently detected intense constitutive
expression of FGF-2 mRNA and protein was the arterial
endothelium. Less consistently, FGF-2 expression was
identified in capillary and venous endothelium, as well
as in vascular smooth muscle cells. Using frozen sections,
others have detected FGF-2 in the basement membrane
of normal human blood vessels and/or occasional capil-
lary endothelial cells [21, 22]. Similar to this study, Stein-
Oakley et al described prominent endothelial expression
of FGF-2 in normal human kidney using formalin-fixed,
paraffin-embedded material [25]. Combined with our
demonstration of FGFR1 expression in vascular smooth
muscle cells, where FGFR1 is the predominantly ex-
Fig. 13. Tubular expression of fibroblast growth factor receptor-1 pressed FGFR type [48], the intense endothelial FGF-2
(FGFR1) protein. (A) Adult medulla, polyclonal antibody Flg/C-15. expression provides the basis for a paracrine pathway of
FGFR1 is expressed in some cells of collecting ducts and some cells of
FGF-2 signaling. The functional relevance of this path-loops of Henle. (B) Normal medulla, monoclonal antibody VBS.
FGFR1 is expressed to a variable degree in cells of a collecting duct. way is supported by several experiments in rats, in which
arteries were mechanically wounded and which demon-
strate that FGF-2 released from injured cells of the vascu-
lar wall mediates smooth muscle proliferation as well asobservations in humans, in that FGF-2 immunoreactivity
angiogenesis [49–51]. The exogenous administration ofwas described in the S3 segments of proximal tubules,
FGF-2 has also been shown to promote endothelial re-thick ascending limbs of the loop of Henle, distal tubules,
generation after injury in rats [52]. This suggests that, atand collecting ducts [36]. Our parallel demonstration
least in the rat, endothelial cells also express FGFR.of high-level FGFR1 protein and mRNA expression in
Our failure to detect FGFR1 on endothelial cells maysome, but not all, cells of the distal nephron suggests that
therefore relate to low-grade expression in humans orFGF-2 may have an important physiological autocrine
suggest that FGFRs other than FGFR1 are predomi-or paracrine role in the maintenance of tubular and/or
nantly expressed on these cells.peritubular functions. The pathophysiological relevance
In summary, we describe the renal expression ofof FGFR1 expression in these sites is indicated by studies
FGF-2 and FGFR1 in mature human kidney. One of thein which chronic, high-dose administration of FGF-2 to
important findings of this study is that despite consider-rats or cynomolgus monkeys induced tubular dilation
able effort, it was not always possible to clarify defini-and cast formation [45]. It is also of interest in this context
tively whether these proteins, especially FGF-2, are ex-that Kanda et al have shown that antagonism of FGF-2
pressed at particular sites. Given the complexity of thein rats with a neutralizing antibody reduced peritubular
FGF system, the clarification of these open questionsendothelial but not tubular cell proliferation during the
may be a difficult task. On the other hand, we providecompensatory growth that follows uninephrectomy [46].
evidence for definitive expression of FGF-2 and FGFR1Because compensatory growth of tubules is mostly de-
in the vascular wall and cells of the distal nephron. Theserived from proximal tubular cells [47], these data appear
data will serve to explain the pathophysiological role ofcompatible with our findings, which showed that these
cells fail to express FGF-2 and FGFR1. FGF-2 in health and disease.
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